June 2024 PVRI Community Call with Julien Grynblat, David Montani and Stravros Zanos

Pulmonary arterial hypertension (PAH) is a chronic, progressive, and ultimately life-threatening disease characterized by vascular remodeling and increasing pulmonary vascular resistance. Despite significant advances in diagnostic tools and therapeutic strategies, clinical intervention often begins only when patients become symptomatic—typically at New York Heart Association (NYHA) functional class II or higher.

Macitentan 10 mg and tadalafil 40 mg single-tablet combination therapy (M/T STCT) has been evaluated in the global A DUE study (NCT03904693). Here, we report the results of a subgroup analysis in participants from China.

In this PH Community Call we discussed: 

• Adventitial fibroblasts direct smooth muscle cell-state transition in pulmonary vascular disease
• Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in ILD-PH: A PVRI GoDeep Meta-Registry Analysis 

In 1976, my wife and I moved to Salt Lake City to start my fellowship in pulmonary and critical care medicine. The University of Utah program had applied principles of physiology to the care of critically ill patients; and that interested me. As a critical care fellow, I learned to perform pulmonary artery catheterization and to interpret hemodynamic measurements in patients with adult respiratory distress syndrome (ARDS).